Cargando…

MYD88(L265P) and MYD88(other) variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma

PURPOSE: This study aims to investigate the clinical and molecular differences between diffuse large B-cell lymphoma (DLBCL) patients with MYD88(L265P) and MYD88(other). METHODS: DLBCL patients with MYD88 variations were collected from the Cancer Hospital, Chinese Academy of Medical Sciences & P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Yan, Qiu, Tian, Xie, Zucheng, Chen, Xinrui, Liu, Peng, Yang, Jianliang, He, Xiaohui, Gui, Lin, Zhou, Shengyu, Jiang, Hongxin, Zhang, Changgong, Yang, Sheng, Tang, Le, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374827/ https://www.ncbi.nlm.nih.gov/pubmed/37093346 http://dx.doi.org/10.1007/s00432-023-04714-1

Ejemplares similares

Preneoplastic somatic mutations including MYD88(L265P) in lymphoplasmacytic lymphoma
por: Rodriguez, Sara, et al.
Publicado: (2022)

Schnitzler syndrome associated with MYD88 L265P mutation
por: Goodman, Aaron M., et al.
Publicado: (2019)

Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
por: Lee, Ju-Han, et al.
Publicado: (2017)

MYD88 L265P mutation in intraocular lymphoma: A potential diagnostic marker
por: Narasimhan, Sandhya, et al.
Publicado: (2020)

PB2403: THE FREQUENCY OF L265P MUTATION IN MYD88 GENE AT DIFFUSE LARGE B-CELL LYMPHOMA
por: Dubrovina, Anastasiya, et al.
Publicado: (2023)

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
por: Munshi, Manit, et al.
Publicado: (2020)

Loss of TNFAIP3 enhances MYD88(L265P)-driven signaling in non-Hodgkin lymphoma
por: Wenzl, Kerstin, et al.
Publicado: (2018)

Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma
por: Baloda, Vandana, et al.
Publicado: (2022)

Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR
por: Niu, Jing, et al.
Publicado: (2020)

Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas
por: Shin, Sang-Yong, et al.
Publicado: (2016)

Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance
por: Wang, James Q., et al.
Publicado: (2014)

Determination of MYD88(L265P) mutation fraction in IgM monoclonal gammopathies
por: Bagratuni, Tina, et al.
Publicado: (2022)

HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
por: Nelde, Annika, et al.
Publicado: (2016)

Correction: Mu heavy chain disease with MYD88 L265P mutation: An unusual manifestation of lymphoplasmacytic lymphoma
por: Baloda, Vandana, et al.
Publicado: (2022)

High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment
por: Yu, Sisi, et al.
Publicado: (2018)

L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma
por: Mori, Naoki, et al.
Publicado: (2013)

Droplet Digital PCR Assay for MYD88(L265P): Clinical Applications in Waldenström Macroglobulinemia
por: Lo Schirico, Mariella, et al.
Publicado: (2020)

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
por: Ansell, S M, et al.
Publicado: (2014)

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88(L265P) Mutation
por: Lynch, Ryan C., et al.
Publicado: (2017)

Detection of the MYD88 p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma
por: Zorofchian, Soheil, et al.
Publicado: (2018)

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
por: Quaglia, Francesca Maria, et al.
Publicado: (2019)

Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma
por: Yamagishi, Yuki, et al.
Publicado: (2021)

Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88(L265P) in Waldenström Macroglobulinemia
por: Kofides, Amanda, et al.
Publicado: (2021)

MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity
por: Saikh, Kamal U.
Publicado: (2021)

Schisandrin B Attenuates Diabetic Cardiomyopathy by Targeting MyD88 and Inhibiting MyD88‐Dependent Inflammation
por: Luo, Wu, et al.
Publicado: (2022)

Identification and Function of Myeloid Differentiation Factor 88 (MyD88) in Litopenaeus vannamei
por: Zhang, Shuang, et al.
Publicado: (2012)

MYD88 L265P Mutations Are Correlated with 6q Deletion in Korean Patients with Waldenström Macroglobulinemia
por: Kim, Jung-Ah, et al.
Publicado: (2014)

MYD88(L265P) Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation
por: Ferrante, Martina, et al.
Publicado: (2021)

MyD88 deficiency aggravates the severity of acute pancreatitis by promoting MyD88-independent TRIF pathway-mediated necrosis
por: Yang, Du-Jiang, et al.
Publicado: (2022)

A MyD88 meddles with survival
por: Bashyam, Hema
Publicado: (2007)

Role of MyD88 in Adenovirus Keratitis
por: Zhou, Xiaohong, et al.
Publicado: (2016)

Effectiveness of digital PCR for MYD88(L265P) detection in vitreous fluid for primary central nervous system lymphoma diagnosis
por: Chen, Kun, et al.
Publicado: (2020)

Rapid detection of the MYD88 L265P mutation for pre‐ and intra‐operative diagnosis of primary central nervous system lymphoma
por: Yamaguchi, Junya, et al.
Publicado: (2023)

The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma
por: Elbaz, Osama, et al.
Publicado: (2023)

Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma
por: Ebid, Osama Abd El Hameed, et al.
Publicado: (2023)

Soyasaponins reduce inflammation by downregulating MyD88 expression and suppressing the recruitments of TLR4 and MyD88 into lipid rafts
por: Chen, Junbin, et al.
Publicado: (2020)

Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features
por: Shuai, Wen, et al.
Publicado: (2020)

MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience
por: Curran, Olimpia E, et al.
Publicado: (2021)

Occurrence of MYD88L265P and CD79B mutations in diffuse large b cell lymphoma with bone marrow infiltration: A case report
por: Huang, Wen-Ye, et al.
Publicado: (2022)

Myd88 Is Required for an Antibody Response to Retroviral Infection
por: Browne, Edward P., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_d2sv2j66og7ejg14hmoelptdt8